2021
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
Kim A, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams B, Mohammadi A, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt E. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery 2021, 89: s16-s16. PMCID: PMC8600280, DOI: 10.1093/neuros/nyaa071_s016.Peer-Reviewed Original Research
2020
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
Kim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams BJ, Mohammadi AM, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt EC. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery 2020, 87: e338-e346. PMID: 32315434, PMCID: PMC7534487, DOI: 10.1093/neuros/nyaa071.Peer-Reviewed Original ResearchConceptsKarnofsky performance scorePrimary tumorBaseline Karnofsky performance scoreCancer Therapy-BrainPostprocedure hospital stayReal-world registryPatient-reported QOLNeurological tissuesHigh-grade gliomasQuality of lifeReal-world outcomesBaseline comorbiditiesHospital stayAdverse eventsMost patientsOverall survivalMedian ageBrain tumor ablationRadiation necrosisPatient populationMetastatic cancerFunctional assessmentSurvival rateBaseline levelsQoL
2018
SURG-06. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY
Kamath A, Tatter S, Fecci P, Chen C, Chiang V, Rao G, Mohammadi A, Judy K, Field M, Neimat J, Leuthardt E, Kim A. SURG-06. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY. Neuro-Oncology 2018, 20: vi251-vi251. PMCID: PMC6216263, DOI: 10.1093/neuonc/noy148.1042.Peer-Reviewed Original ResearchLaser interstitial thermal therapyBrain metastasesProcedural dataDeath rateAblation coverageMedian overall survivalAcceptable safety profileSingle-center experienceDay of procedureKaplan-Meier survivalNeurological tissuesAverage lesion volumeLocation of lesionsPreliminary outcomesInterstitial thermal therapyAdverse eventsOngoing registryOverall survivalCenter experienceSafety profileMean ageInvasive optionTarget lesionsProcedural efficacyLesion volume